Mounjaro®
Starting from £179.99/mo
Start journey Learn moreEach Mounjaro dose stays active in the body for roughly one week, which is exactly why it is injected once every seven days. Tirzepatide has a half-life of approximately five days, meaning it gradually reduces between doses rather than switching off abruptly. That steady, week-long presence is what makes the once-weekly schedule work. As with all prescription-only medicines, a qualified prescriber assesses whether Mounjaro is clinically appropriate for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is a question our prescribers hear most weeks, and the honest answer is that there are at least three different things people are asking. First, how long a single dose remains pharmacologically active in the body. Second, how long an open or unopened pen stays usable before it must be discarded. Third, how long the weight-management effects persist once treatment ends. Each has a different answer, and muddling them leads to real confusion about the schedule.
The pharmacological question has a precise answer: tirzepatide's half-life is around five days. A drug's half-life is the time it takes for the concentration in your bloodstream to fall by half. At that rate, each weekly dose is still meaningfully present when the next one is due, which is why the seven-day interval keeps levels stable rather than letting them crash and recover. You can read a detailed look at what happens between doses on our page about how long tirzepatide lasts, which covers the pharmacokinetics in more depth. The NHS's medicines page for tirzepatide is also a reliable starting point for understanding the basics of how the medicine works.
The short version: one dose, one week of activity. After that, the next injection keeps things going. That rhythm matters more than any single dose taken in isolation.
The Mounjaro KwikPen is pre-filled with four weekly doses. Once you inject the first dose, the clock starts on the pen itself. Storage conditions determine how long those remaining doses stay safe and effective to use, and the Patient Information Leaflet sets out the exact permitted window. Always follow the leaflet rather than memory or online advice, because the limits reflect stability data rather than a rough estimate.
Before first use, pens are stored in the fridge at 2–8°C. After opening, there is a defined room-temperature window during which an un-refrigerated pen remains usable. For the specific number of days, our guide to Mounjaro pen duration after opening sets out the current guidance in full. If a pen has been left outside the fridge for longer than permitted, the right call is to contact your prescriber or pharmacist before injecting.
Separately, unopened pens have their own shelf life. If you have a pen you have not yet started, the question of expiry dates and storage is covered on the page about how long Mounjaro lasts unopened. Worth checking before treatment begins.
This is where expectations and reality most often diverge. A single dose does not produce a week's worth of dramatic results. The appetite-suppressing effect of each injection is real and relatively rapid, but the weight change that follows accumulates over months. In the SURMOUNT-1 clinical trial, published in the New England Journal of Medicine, participants receiving the highest dose achieved average body-weight reductions of around 20–21% across 72 weeks. Those results arrived through consistent, gradual progress, not a steep early drop.
Many people notice reduced appetite and some early weight change in the first few weeks. The pace then varies considerably between individuals depending on starting weight, diet, activity levels, and the dose reached after titration. Our page on how long Mounjaro takes to work goes into the timeline in more detail, and our guide on supporting weight loss on Mounjaro covers the lifestyle factors that make the most difference alongside the medicine.
If you experience bloating or digestive discomfort, particularly in the early weeks or after a dose increase, that too settles at its own pace. The duration of Mounjaro-related bloating varies but is typically temporary and most pronounced when the body is adjusting to a new dose level.
Once treatment ends, tirzepatide clears the body over several weeks as it continues to fall through successive half-lives. The appetite-reduction effect eases during this period rather than stopping sharply. Weight regain after stopping GLP-1 medicines is a well-documented pattern in the clinical literature, which is why the licensed indication situates Mounjaro within an ongoing lifestyle programme rather than as a short-term fix.
For people considering the full picture of cost and duration of treatment, our Mounjaro cost page sets out what private treatment includes and how pricing works. And if you want a broader overview of Mounjaro as a treatment, the Mounjaro treatment page covers eligibility, how the medicine is prescribed, and what to expect from the process at nume.
Deciding how long to stay on treatment is a clinical question, not a personal one to make alone. A prescriber reviews your progress and circumstances at each repeat, which is how it should work for a prescription medicine with this level of effect on the body. If you are ready to talk through whether Mounjaro is appropriate for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.